x min read

Stocks In Focus: Telef (NYSE:TEF), Honeywell International Inc. (NYSE:HON), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Stocks In Focus: Telef (NYSE:TEF), Honeywell International Inc. (NYSE:HON), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Written by
Aaron Smith
Published on
October 20, 2014
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook
InsidrFinancial

Telefonica S.A. (ADR) (NYSE:TEF) declared that its plan to cut 1,600 full-time positions by 2018. The firm reported that the job reductions will not differentiate among the old Telefónica Deutschland and the former E-Plus Group, and is mainly to abolish duplicate functions. Telefonica S.A. (ADR) (NYSE:TEF) stock hit highest price at $14.12, beginning with a price of $14.10 to the closed at 14.05 by an increase of 0.43% with a day range of $14.01-$14.12. The total market capitalization remained 62.846 Billion, total volume of 1.4 Million shares held in the session was surprisingly higher than its average volume of 1079.64 shares.Diversified technology and manufacturing company, Honeywell International Inc. (NYSE:HON) released higher third-quarter 2014 net income attributable to the firm of $1.17B, or $1.47 per share, against the previous year's $990M, or $1.24 a share. Analysts polled by Thomson Reuters anticipates the firm to report earnings of $1.41 a share for the quarter. Analysts' anticpates typically exclude special items. Shares of Honeywell International Inc. (NYSE:HON) opened at $89.20 with 782.54 million outstanding shares and hit to its highest price of $90.78 during the day and finally closed at $90.06 by scoring 4.25%. In the whole session, it traded on volume of 7.83 Million shares, which turned higher than its average volume.Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) recently declared that its EYLEA injection demonstrated considerably greater gains in visual acuity than both bevacizumab as well as ranibizumab, in an NIH-sponsored diabetic macular edema or DME study. The independent, government-sponsored trial was designed to find if one of the three different anti-VEGF therapies is superior to the others for the treatment of DME. On the other consideration, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) begun last trade with a price of $366.00 and throughout the trading session climbed at $376.88. The day-trade ended with an increase of 8.49% to closed at $369.64. The stock is going forward its fifty-two week low with 43.44% and lagging behind from its 52 week high price with 0.09%. REGN last month stock price volatility remained 2.89%.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.